Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Carrie L, Dul"'
Autor:
Jason A. Mouabbi, Momal Chand, Ishaq A. Asghar, Ramen Sakhi, Daniel Ockner, Carrie L. Dul, Tarik Hadid, Amr Aref, Mothaffar F. Rimawi, Valentina Hoyos
Publikováno v:
Cancer Medicine, Vol 10, Iss 14, Pp 4790-4795 (2021)
Abstract Objective The goal was to compare the 5‐year DFS and 5‐year OS in patients with early‐stage human epidermal growth factor receptor 2 breast cancer (HER2+ BC) and triple‐negative breast cancer (TNBC) in relation to the amount of strom
Externí odkaz:
https://doaj.org/article/c6a62fe8c1c74ba0a71fb27937d91dca
Autor:
Dawn L. Hershman, Aasthaa Bansal, Sean D. Sullivan, William E. Barlow, Kathryn B. Arnold, Kate Watabayashi, Ari Bell-Brown, Nguyet A. Le-Lindqwister, Carrie L. Dul, Ursa A. Brown-Glaberman, Robert J. Behrens, Victor Vogel, Nitya Alluri, Scott D. Ramsey
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
PURPOSE Primary prophylactic colony-stimulating factors (PP-CSFs) are prescribed to reduce febrile neutropenia (FN) but their benefit for intermediate FN risk regimens is uncertain. Within a pragmatic, randomized trial of a standing order entry (SOE)
Autor:
Pat W. Whitworth, Peter D. Beitsch, Mary K. Murray, Paul D. Richards, Angela Mislowsky, Carrie L. Dul, James V. Pellicane, Paul L. Baron, Rakhshanda Layeequr Rahman, Laura A. Lee, Beth B. Dupree, Pond R. Kelemen, Andrew Y. Ashikari, Raye J. Budway, Cristina Lopez-Penalver, William Dooley, Shiyu Wang, Patricia Dauer, Andrea R. Menicucci, Erin B. Yoder, Christine Finn, Lisa E. Blumencranz, William Audeh
Publikováno v:
JCO precision oncology. 6
PURPOSE The prospective Neoadjuvant Breast Registry Symphony Trial compared the 80-gene molecular subtyping signature with clinical assessment by immunohistochemistry and/or fluorescence in situ hybridization in predicting pathologic complete respons
Autor:
Momal Chand, Valentina Hoyos, Jason A Mouabbi, Daniel Ockner, Mothaffar F. Rimawi, Amr Aref, Tarik Hadid, Ramen Sakhi, Carrie L. Dul, Ishaq A. Asghar
Publikováno v:
Cancer Medicine, Vol 10, Iss 14, Pp 4790-4795 (2021)
Cancer Medicine
Cancer Medicine
Objective The goal was to compare the 5‐year DFS and 5‐year OS in patients with early‐stage human epidermal growth factor receptor 2 breast cancer (HER2+ BC) and triple‐negative breast cancer (TNBC) in relation to the amount of stromal tumor
Autor:
James V. Pellicane, Peter D. Beitsch, David T. Rock, Raye J. Budway, Carrie L. Dul, Pond R. Kelemen, Andrew Y. Ashikari, Paul L. Baron, Paul D. Weinstein, Angela Mislowsky, Laura A. Lee, Jennifer Beatty, Mary K. Murray, Beth B. Dupree, Christine Finn, Kate Corcoran, Shiyu Wang, Andrea R. Menicucci, Erin B. Yoder, Lisa E. Blumencranz, Patricia Dauer, William Audeh, Pat W. Whitworth
Publikováno v:
Surgical oncology. 45
As more patients with early-stage breast cancer receive neoadjuvant endocrine therapy (NET), there is a need for reliable biomarkers that can identify patients with HR+ HER2- tumors who are likely to benefit from NET. NBRST (NCT01479101) compared the
Autor:
Pat W, Whitworth, Peter D, Beitsch, James V, Pellicane, Paul L, Baron, Laura A, Lee, Carrie L, Dul, Mary K, Murray, Mark A, Gittleman, Raye J, Budway, Rakhshanda Layeequr, Rahman, Pond R, Kelemen, William C, Dooley, David T, Rock, Kenneth H, Cowan, Beth-Ann, Lesnikoski, Julie L, Barone, Andrew Y, Ashikari, Beth B, Dupree, Shiyu, Wang, Andrea R, Menicucci, Erin B, Yoder, Christine, Finn, Kate, Corcoran, Lisa E, Blumencranz, William, Audeh
Publikováno v:
JCO Precision Oncology.
PURPOSE The 80-gene molecular subtyping signature (80-GS) reclassifies a proportion of immunohistochemistry (IHC)-defined luminal breast cancers (estrogen receptor–positive [ER+], human epidermal growth factor receptor 2–negative [HER2–]) as Ba
Autor:
Kathryn F. Mileham, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Herbert L. Duvivier, Carmen J. Calfa, Carrie L. Dul, Alissa S. Marr, Eugene R. Ahn, Deepti Behl, Michael J. Hall, Inderjit Mehmi, Anu Gaba, Rom Leidner, Mark M. Zalupski, Gina N. Grantham, Abigail Gregory, Susan Halabi, Richard L. Schilsky
Publikováno v:
Cancer Research. 83:CT226-CT226
Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohort of pts with solid tumors and MET amp or mut treat
Autor:
Rohit Kumar, Tarik Hadid, Sindhu Janarthanam Malapati, Sunny Rk Singh, Jason A Mouabbi, Ahmed Abdalla, Carrie L. Dul
Publikováno v:
Cancer Research. 80:P2-08
Background: The utilization of bilateral (B/L) mastectomy for ductal carcinoma in situ (DCIS) has been rising within the last two decades. This is occurring despite the lack of convincing evidence to support the positive impact of this approach on di
Autor:
Ramen Sakhi, Amr Aref, Daniel Ockner, Jason A Mouabbi, Carrie L. Dul, Zyad Kafri, Tarik Hadid, Susan Szpunar, Momal Chand
Publikováno v:
Cancer Research. 80:P4-12
Background: There is a strong evidence indicating that locoregional control of early-stage breast cancer either by lumpectomy with radiation therapy or by mastectomy yields similar rates of disease-free survival (DFS) and overall survival (OS). Recen
Autor:
Pat, Whitworth, Peter D, Beitsch, James V, Pellicane, Paul L, Baron, Laura A, Lee, Carrie L, Dul, Charles H, Nash, Mary K, Murray, Paul D, Richards, Mark, Gittleman, Raye, Budway, Rakhshanda Layeequr, Rahman, Pond, Kelemen, William C, Dooley, David T, Rock, Ken, Cowan, Beth-Ann, Lesnikoski, Julie L, Barone, Andrew Y, Ashikari, Beth, Dupree, Shiyu, Wang, Andrea R, Menicucci, Erin B, Yoder, Christine, Finn, Kate, Corcoran, Lisa E, Blumencranz, William, Audeh
Publikováno v:
Annals of surgical oncology.
The Neoadjuvant Breast Symphony Trial (NBRST) demonstrated the 70-gene risk of distant recurrence signature, MammaPrint, and the 80-gene molecular subtyping signature, BluePrint, precisely determined preoperative pathological complete response (pCR)